Should Enveric Biosciences be in Your Stock Portfolio?

: ENVB | Enveric Biosciences Inc. News, Ratings, and Charts

ENVB – Enveric Biosciences (ENVB) garnered significant market attention, announcing its proposed acquisition of MagicMed in May 2021. However, is it smart to bet on the stock now, as it has yet to generate revenue? Let’s find out.

Early-development-stage biosciences company Enveric Biosciences, Inc. (ENVB) is engaged in developing various cannabinoid-based solutions to treat those adversely affected by the side effects of cancer treatments. Its shares soared 10.5% over the past three months on the back of investor optimism surrounding the proposed acquisition of MagicMed Industries Inc. This could help ENVB expand its oncology and central nervous system (CNS) product portfolio.

However, investigations are ongoing against ENVB regarding the proposed acquisition, which could negatively impact the company’s business. The stock has lost 38.3% year-to-date and 60.4% over the past nine months to close Friday’s trading session at $2.63. Moreover, the company is yet to generate revenue, and its losses widened in the second quarter. So, its near-term prospects look uncertain.

Here’s what I think could influence ENVB’s performance in the near term:

Positive Developments

On July 8, ENVB announced that it received approval from the Israeli Ministry of Health to begin the Phase 1/2 portion of its study of its lead asset, EV101, designed to investigate the safety and efficacy of synthetic cannabidiol (CBD) treatment for glioblastoma (GBM). However, the product is not yet approved for marketing. Also, on May 24, ENVB agreed to acquire MagicMed Industries Inc., subject to shareholder approval.

Diverse Biotech announced in March 2021 that it had finalized a strategic transaction with ENVB to license exclusive worldwide development and commercialization rights for five novel compounds to address the side effects of cancer treatments. Also, ENVB launched a strategic development collaboration and exclusive supply agreement with PureForm Global, Inc. in February 2021 to treat pain and inflammation resulting from cancer treatments.

Click here to checkout our Healthcare Sector Report for 2021

Ongoing Investigation

Following ENVB’s announcement of the proposed acquisition of MagicMed, several law firms launched an investigation against ENVB on potential violations of the federal securities laws and breaches of fiduciary duties. Upon completion of the transaction, ENVB’s current shareholders are expected to own roughly 63.4% of the combined company’s common stock. Moreover, class action law firm Purcell Julie & Lefkowitz LLP had launched an investigation against ENVB in January 2021 on a potential breach of fiduciary duty claim involving its board of directors.

Weak Financials

ENVB’s research and development costs increased 1,626.6% year-over-year to $879,843 for the second quarter that ended June 30, 2021. The company’s general and administrative expenses increased 222.3% from the same period last year to $2.31 million. While its loss from operations increased 338.2% year-over-year to $3.36 million, its net loss came in at $908,289, up 11% year-over-year. Its loss per share came in at $0.04 in the quarter compared to a loss of $0.15 in the year-ago period.

POWR Ratings Don’t Indicate Enough Upside

ENVB has an overall grade of C, which equates to a Neutral rating in our POWR Ratings system. The POWR Ratings are calculated by taking into account 118 different factors, with each factor weighted to an optimal degree.

Our proprietary ratings system also evaluates each stock based on eight different categories. ENVB has a C grade for Growth, consistent with analysts’ expectations that its EPS will remain negative in the current year and next year.

The stock has a D grade for Momentum, in sync with its 18.3% loss over the past six months and 60.4% loss over the past nine months. Moreover, ENVB has a D grade for Stability.

ENVB is ranked #149 out of 510 stocks in the Biotech industry. Click here to see the additional grades for ENVB (Value, Sentiment, and Quality).

Bottom Line

Even though ENVB did not have an impressive stock market debut last year, it has made several advances in developing solutions to treat cancer patients. However, it is still in the early stages of development. Moreover, its near-term prospects look uncertain due to the investigations against it regarding the proposed acquisition of MagicMed. So, it could be wise to wait before adding the stock to your portfolio.

How Does Enveric Biosciences (ENVB) Stack Up Against its Peers?

ENVB has an overall grade of C. However, check out these A-rated (Strong Buy) stocks in the Biotech industry: Sino Biopharmaceutical Limited (SBHMY), QIAGEN N.V. (QGEN), and Takeda Pharmaceutical Company Limited (TAK).


ENVB shares were trading at $2.66 per share on Tuesday morning, up $0.03 (+1.14%). Year-to-date, ENVB has declined -37.56%, versus a 21.45% rise in the benchmark S&P 500 index during the same period.


About the Author: Manisha Chatterjee


Since she was young, Manisha has had a strong interest in the stock market. She majored in Economics in college and has a passion for writing, which has led to her career as a research analyst. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
ENVBGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Updated 2024 Stock Market Outlook

The bull market continues to rage on with the S&P 500 (SPY) making new highs. That is the past...the question is what does the future hold? That is why 44 year investment veteran Steve Reitmeister provides this updated 2024 Stock Market Outlook to help you carve a path to outperformance the rest of the year. Read on below for the full story...

3 Energy Stocks Set to Soar Beyond Expectations

Given the geopolitical tensions, increasing global oil demand, and supply adjustments, the energy sector is poised for robust growth. Therefore, investors might consider investing in energy stocks TechnipFMC (FTI), Weatherford International (WFRD), and ChampionX (CHX), which are poised to exceed expectations. Keep reading…

Has Carnival (CCL) Stock Turned Into a Buy After Earnings Release?

Carnival Corporation (CCL) reported record revenue in its most recent quarter but still faces a negative bottom line. The collapse of Francis Scott Key Bridge brings more uncertainty to its financials. Given these events, what stance should one take with CCL stock? Read more to find out…

3 China Stocks Positioned for Long-Term Growth

Despite facing challenges, the Chinese economy has demonstrated resilience, as evidenced by recent robust industrial output and retail sales data. Given this outlook, it might be an opportune time to own three top-notch China stocks, JD.com, Inc. (JD), China Automotive Systems (CAAS), and Youdao, Inc. (DAO). Read on…

Investor Alert: “Buy the Rumor, Sell the News!”

Everyone knows that the Fed is going to cut rates at some point this year. That is the worst kept secret on the planet helping to explain how we keep making new highs for the for the S&P 500 (SPY). Unfortunately that creates an interesting predicament for stocks after rates are cut. Plus another hurdle in the 2024 Presidential election. Steve Reitmeister is here to share his insights on the market outlook along with a preview of his top 12 stocks to outperform. Read on for more...

Read More Stories

More Enveric Biosciences Inc. (ENVB) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ENVB News